Date: October 10, 2023
Time: 9:00am PDT, 11:00am CDT, 12:00pm EDT
Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhibitors, induce synthetic lethality in tumors with high levels of HRD. When Genome-wide HRD severity is scored, studies show these scores correlate to PARP inhibitor response. In this webinar the speakers will review their experiences using OncoScan, a whole-genome research microarray, as an alternative to NGS to detect Long Scale State transitions (LST), Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI) and Whole Genome Doubling (WGD) events, to create HRD Scores.
- Linking HRD scaring biology to PARP inhibitor response.
- Comparing methods for detecting HRD – the benefits and challenges.
- Implementing OncoScan successfully in a clinical research lab to understand HRD in samples.
- Understanding future directions for HRD into new tumor entities and technology development.
For research use only. Not for use in diagnostic procedures.
Webinars will be available for unlimited on-demand viewing after live event.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.